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TO THE EDITOR
Although different authors have con-
firmed the involvement of T cells in
delayed-type hypersensitivity reactions
to glucocorticosteroids (GCs) in skin
biopsies (Padial et al., 2005) or by
specific lymphocyte responses (Buettiker
et al., 2006), the underlying mechanisms
are complex, because both the antiin-
flammatory and pro-allergic effects may
take place at the same time.
Dendritic cells (DCs) are central to
the development of specific effector
and tolerant immunological responses
(Steinman et al., 2003). Low-molecular-
weight compounds, including drugs,
are able to induce DC maturation
(Manome et al., 1999; Rodriguez-Pena
et al., 2006), which could be respon-
sible for the loss of tolerance to these
molecules. However, some drugs, such
as GCs, can inhibit the generation of
mature DCs (Pan et al., 2001), thereby
hindering the evaluation of the way this
drug is involved in delayed-type hyper-
sensitivity reactions.
We report a 40-year-old man
with rhinoconjunctivitis sensitized to
pollens, who developed a generalized
exanthema 5 days after starting treat-
ment with nasal budesonide (Rhinocort,
Astra, Lund, Sweden) and 8 hours after
the last inhalation. A patch test was
positive with budesonide and the skin
biopsy showed a perivascular mono-
nuclear cell infiltrate, with the presence
of CD4þ and, to a lesser degree,
CD8þ cells, detected by immunohisto-
chemistry. These cells were memory
cells (CD45ROþ ), with a moderate
expression of the activation marker
CD25. Patch and drug provocation tests
were negative with dexamethasone,
beclomethasone, methylprednisolone,
and hydrocortisone.
In this patient and in five healthy
nonallergic controls who tolerated the
drug, we analyzed the in vitro immuno-
logical response to different GCs by
culturing autologous lymphocytes with
and without monocyte-derived DCs
(mo-DCs) and evaluated the specific
lymphocyte proliferation, their activa-
tion markers, and the changes in the
maturational phenotype of DCs.
Peripheral blood mononuclear cells
were isolated and cultivated in complete
medium (RPMI-1640 medium with 10%
autologous serum). The nonadherent
cells containing lymphocytes were fro-
zen for future use, and the adherent cells
(monocytes) were cultured in 2 ml of
complete medium supplemented with
GM-CSF (R&D System, Minneapolis,
MN) (800 U ml1) and IL-4 (R&D
System) (500 U ml1) for 4 days to obtain
mo-DCs.
For proliferation assays, lympho-
cytes were cultured in 96-well plates
in triplicate, with or without mo-DCs
(150,000 lymphocytes and 15,000 DCs
per well), and with budesonide,
methylprednisolone, and hydrocorti-
sone at 10mg ml1, 0.1 mg ml1, and
0.001mg ml1, respectively. After 6
days, 3H-Thymidine incorporation was
evaluated in a b-counter as counts per
minute. The stimulation index (SI) was
calculated as the ratio of the mean
counts per minute of a drug-stimulated
sample to the mean counts per minute
of the sample alone. An SI43 was
considered positive.
For phenotype analysis, a panel
of mAbs (HLA-DR-FITC, CD86-FITC,
CD80-PE CD40-PE, and CD83-PE
for mo-DC, and CD4-FITC, CD25-PE,
HLA-DR-PE, CD3-PerCP, and CD8-APC
for lymphocytes) and an FACSCalibur
cytometer were used.
In the patient, lymphocyte prolifera-
tion tests were positive only with
budesonide (SI¼ 3.4), although higher
in the presence of mo-DCs (SI¼ 6.8),
and in both cases, only at the lowest
drug concentration (0.001mg ml1).
Abbreviations: DC, dendritic cell; GC, glucocorticosteroid; mo-DC, monocyte-derived dendritic cell; SI,
stimulation index
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Results were negative for the other GCs
tested. Lymphocyte phenotype analysis
after incubation with budesonide with
or without DCs (Figure 1 and Supple-
mentary Figure S1) showed an increase
in CD25 and HLA-DR expression only
in the CD4þ T cells when cultured
with mo-DCs at the lowest concentra-
tion. Independent of the addition of the
drug, there was an increase in
CD4CD25high cells. DC phenotype
analysis showed that budesonide at
0.001mg ml1 induced an increase in
the HLA-DR surface density, especially
in the presence of lymphocytes, and a
minor increase in CD86 (Supple-
mentary Figure S2).
In controls, the lymphocyte prolif-
eration test was negative with all GCs
used. Regarding changes in DC and
lymphocyte phenotypes when cultured
with budesonide, we only detected a
low decrease in HLA-DR and CD86
molecules in DCs, as well as in the
percentage of CD4 and CD8 T lympho-
cytes expressing HLA-DR, at higher
doses (10 mg ml1) (Figure 1, Supple-
mentary Figures S1 and S2).
In this study, we showed that the
addition of DCs improved the prolif-
erative response of the classic lympho-
cyte proliferation assays in this patient
with a T-lymphocyte-mediated reac-
tion. This can be explained because
DCs are very potent antigen-presenting
cells, which can stimulate both mem-
ory and naive T cells, as well as effector
and tolerant subsets. The analysis of the
interaction between the culprit drug
(budesonide) and the patient’s DC
showed that the drug is able to induce
changes in the cell phenotype by itself,
and although we cannot define the
resulting phenotype as a complete ma-
turation status, it seems a more matura-
tive phenotype than that detected
without the drug or in controls, espe-
cially in terms of the number of HLA-DR
and CD86 molecules on their surfaces.
Moreover, the presence of the autolo-
gous lymphocytes seems to contribute
to the increased maturation of the
DCs induced by the drug. This could
be because of a bystander relation-
ship between the activated lymphocytes,
the DCs, and the antigens presented,
as seen with other haptens (Manome
et al., 1999; Rodriguez-Pena et al.,
2006).
The model of delayed-type hyper-
sensitivity to GCs is complex because
of the antiinflammatory and immuno-
suppressor effects of these drugs (Pan
et al., 2001), seen by us in terms of
increased regulatory T lymphocytes in
both patients and controls, and by
others who have shown that GCs
promote the differentiation of these
cells (Karagiannidis et al., 2004).
However, this suppressor effect
seems to be abrogated if we use very
low doses of the drugs, which are not
sufficient to inhibit the immune system
but still conserve their antigenic poten-
tial. These preliminary data provide
important information for studying the
mechanisms involved in delayed-type
hypersensitivity reactions to GCs. Fur-
ther studies including a series of cases
are warranted.
This study was approved by the
relevant institutional review boards,
and informed consent for the diagnostic
procedures was obtained from the
patients and controls following the
Helsinki Guidelines.
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Figure 1. CD4 and CD8 lymphocyte activation markers and CD25high expression in culture with autologous dendritic cells plus budesonide in the patient (a)
and controls (b).
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TO THE EDITOR
Although the incidence of melanoma is
still rising in many countries, the exact
molecular pathogenesis for this tumor is
unknown. Consequently, the publica-
tion of the study by Davies et al. (2002)
reporting a high frequency of activating
BRAF mutations in melanoma attracted
much attention in the research commu-
nity. Indeed, many independent groups
have confirmed the high frequency of
BRAF mutations in patients with mela-
noma; the mutation data on the COS-
MIC website (http://www.sanger.ac.uk/
genetics/CGP/cosmic/) indicate that
BRAF mutations were detected in 46%
of melanoma patients (n¼3,634), with
BRAF V600E being the predominant
mutation, found in 37.2% of the ana-
lyzed patients. However, given that in
benign melanocytic nevi the frequency
of BRAF mutations is similarly high
(35% total mutations; 29.5% BRAF
V600E; n¼830, including 358 Spitz
and blue nevi having a BRAF mutation
frequency of B7%), BRAF mutations
alone are not sufficient to initiate
malignant melanoma. This thesis is
sustained by experimental data showing
that ectopic expression of constitutive
active BRAF leads to senescence
of primary cells (Michaloglou et al.,
2005). An autocrine/paracrine regu-
latory loop explaining this observation
was recently described by Wajapeyee
et al. (2008), who demonstrated the
presence in normal cells of a basal
expression of insulin-like growth factor–
binding protein 7 (IGFBP7) that inhibits
BRAF–MEK–ERK signaling and thereby
restrains apoptosis. In nevi, BRAF muta-
tions activating the MAP kinase path-
way lead to an increased expression of
IGFBP7, which not only inhibits BRAF–-
MEK–ERK signaling but also activates
senescence. In contrast, in BRAF-
mutated melanoma lesions, IGFBP7
expression is absent, enabling the cells
to escape from senescence and thereby
exhibit uncontrolled proliferation.
Besides delivering the explanation for
the observed effects of constitutive
BRAF activation, the article by Waja-
peyee and colleagues demonstrates a
potential therapeutic application of this
knowledge: treatment with recombinant
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Figure 1. IGFBP7 expression in melanoma lesions. Primary tumors (a) or metastases (b and c) were
stained with an anti-IGFBP7 antibody. Representative examples of lesions with BRAF mutations showing
IGFBP7 expression (a and b) and with wt BRAF characterized by low IGFBP7 expression (c). (d) The
results for all samples (34 wt and 23 BRAF-mutated lesions) are depicted. There is no significant
difference between the two groups (Mann–Whitney test; P¼0.1609). Bar¼100 mm.
Abbreviation: IGFBP7, insulin-like growth factor–binding protein 7
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